HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NDI Notification Estimate Unchanged: Health And Wellness Industry News

This article was originally published in The Rose Sheet

Executive Summary

Biotek gets FDA's own-labeler lesson; MyNicNaxs shut down after ignoring warning; and FDA sticks with NDI notification cost estimate.

You may also be interested in...



Dr. King's Homeopathics Recalled; MyNicNaxs Starts Recall 3 Months After FDA Shutdown

Dr. King's brand homeopathic Aquaflora Candida HP9, Lymph Detox and Baby Teething liquids are recalled after FDA found microbial contaminants. MyNicNaxs, which was shut down in March, is recalling all supplements it sold for five years. Gaia Ethnobotanical is latest firm recalling kratom-containing supplements due to salmonella.

Injunction Closes Another Supplement Firm: Health And Wellness Industry News

Mannatech slumps on Americas downturn; MusclePharm navigates bumps in turnaround; kratom recalls updated; and FDA, DoJ shutter another supplement firm

NPA Submits Wish List For Reducing FDA Regulatory Burdens Per Trump Order

FDA’s NDI notification draft guidance should be rewritten and its Nutrition Facts and Supplement Facts Final Rule delayed, the Natural Products Association says in comments submitted to the agency in response to President Trump’s executive order aimed at cutting down on burdensome regulations.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel